Simmunome is a techbio company leveraging generative AI to enhance the predictability of clinical drug development. They offer a SaaS-based multimodal disease model platform that integrates data such as genomics and proteomics to simulate patient responses and predict clinical outcomes. The platform optimizes drug development by providing features like biomarker discovery, dose optimization, and patient stratification. Target markets include pharmaceutical companies, biotech firms, and academic institutions, helping them improve R&D efficiency and reduce clinical trial failure rates.